- Home
- IPW vs PULM Comparison
IPW vs PULM Comparison
Compare IPW & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPW
- PULM
- Stock Information
- Founded
- IPW 2018
- PULM 2003
- Country
- IPW United States
- PULM United States
- Employees
- IPW N/A
- PULM N/A
- Industry
- IPW Catalog/Specialty Distribution
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- IPW Consumer Discretionary
- PULM Health Care
- Exchange
- IPW Nasdaq
- PULM Nasdaq
- Market Cap
- IPW 19.8M
- PULM 20.5M
- IPO Year
- IPW 2021
- PULM N/A
- Fundamental
- Price
- IPW $0.57
- PULM $4.71
- Analyst Decision
- IPW
- PULM
- Analyst Count
- IPW 0
- PULM 0
- Target Price
- IPW N/A
- PULM N/A
- AVG Volume (30 Days)
- IPW 91.5K
- PULM 10.4K
- Earning Date
- IPW 09-18-2025
- PULM 08-06-2025
- Dividend Yield
- IPW N/A
- PULM N/A
- EPS Growth
- IPW N/A
- PULM N/A
- EPS
- IPW N/A
- PULM N/A
- Revenue
- IPW $74,105,251.00
- PULM $369,000.00
- Revenue This Year
- IPW $8.31
- PULM N/A
- Revenue Next Year
- IPW $77.15
- PULM $134.88
- P/E Ratio
- IPW N/A
- PULM N/A
- Revenue Growth
- IPW N/A
- PULM N/A
- 52 Week Low
- IPW $0.41
- PULM $1.78
- 52 Week High
- IPW $2.36
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- IPW 36.87
- PULM 32.51
- Support Level
- IPW $0.55
- PULM $4.65
- Resistance Level
- IPW $0.60
- PULM $5.09
- Average True Range (ATR)
- IPW 0.04
- PULM 0.28
- MACD
- IPW -0.01
- PULM -0.01
- Stochastic Oscillator
- IPW 11.62
- PULM 5.38
About IPW iPower Inc.
iPower Inc is online hydroponic equipment and accessory retailer and supplier in North America. The company sells products through own website as well as online channel partners that include Amazon, Walmart, and eBay.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).